{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:00:59Z","timestamp":1784696459262,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00621-1","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:03:20Z","timestamp":1784693000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective"],"prefix":"10.1007","volume":"34","author":[{"given":"Pengxiang","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9848-4868","authenticated-orcid":false,"given":"Aiwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"621_CR1","first-page":"1225","volume":"39","author":"J Li","year":"2023","unstructured":"Li J, Wen H, Liu S, et al. White paper on the current state of ovarian cancer diagnosis and treatment in China in 2023. Chin J Practical Gynecol Obstet. 2023;39:1225\u201332.","journal-title":"Chin J Practical Gynecol Obstet"},{"key":"621_CR2","first-page":"289","volume":"25","author":"J Li","year":"2024","unstructured":"Li J, Jiang J. Targeted Therapy for Ovarian Cancer: Application and Advances. Chin J Clin Obstet Gynecol. 2024;25:289\u201391.","journal-title":"Chin J Clin Obstet Gynecol"},{"key":"621_CR3","first-page":"1901","volume":"40","author":"S Hang","year":"2024","unstructured":"Hang S, Wu Y, Zhang Y. Aiming for the future: The latest advances in targeted therapy for ovarian cancer. J Practical Med. 2024;40:1901\u201307.","journal-title":"J Practical Med"},{"key":"621_CR4","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353.","journal-title":"J Natl Cancer Cent"},{"key":"621_CR5","first-page":"203","volume":"4","author":"H Zeng","year":"2024","unstructured":"Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in China 2019\u20132021: A multicenter, population-based study. J Natl Cancer Cent. 2024;4:203\u201313.","journal-title":"J Natl Cancer Cent"},{"key":"621_CR6","doi-asserted-by":"publisher","first-page":"1589841","DOI":"10.3389\/fbioe.2025.1589841","volume":"13","author":"M Zhang","year":"2025","unstructured":"Zhang M, Zhu J, Bao Y, et al. Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies. FRONT BIOENG BIOTECH. 2025;13:1589841.","journal-title":"FRONT BIOENG BIOTECH"},{"key":"621_CR7","first-page":"689","volume":"54","author":"X Zhou","year":"2025","unstructured":"Zhou X, Liang Z, Liu J, et al. Guideline on clinical practice of molecular testing in ovarian carcinoma. Chin J Pathol. 2025;54:689\u2013700.","journal-title":"Chin J Pathol"},{"key":"621_CR8","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. NEW ENGL J MED. 2019;381:2416\u201328.","journal-title":"NEW ENGL J MED"},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: Final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. ANN ONCOL. 2023;34:681\u201392.","journal-title":"ANN ONCOL"},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","volume":"34","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Mouret-Reynier MA, Harter P, et al. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial. INT J GYNECOL CANCER. 2024;34:550\u201358.","journal-title":"INT J GYNECOL CANCER"},{"key":"621_CR11","volume-title":"China Guidelines for Pharmacoeconomic Evaluation: A Guide 2022","author":"G Liu","year":"2022","unstructured":"Liu G, Wu J, Xie F, et al. China guidelines for pharmacoeconomic evaluation: A guide 2022. Beijing: China Market; 2022."},{"key":"621_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12874-024-02273-8","volume":"24","author":"JZ Zhang","year":"2024","unstructured":"Zhang JZ, Rios JD, Pechlivanoglou T, et al. SurvdigitizeR: An algorithm for automated survival curve digitization. BMC MED RES METHODOL. 2024;24:147.","journal-title":"BMC MED RES METHODOL"},{"key":"621_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC MED RES METHODOL. 2021;21:111.","journal-title":"BMC MED RES METHODOL"},{"key":"621_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s41669-023-00391-5","volume":"7","author":"T Shao","year":"2023","unstructured":"Shao T, Zhao M, Liang L, et al. Impact of extrapolation model choices on the structural uncertainty in economic evaluations for cancer immunotherapy: A case study of checkmate 067. PHARMACOECON-OPEN. 2023;7:383\u201392.","journal-title":"PHARMACOECON-OPEN"},{"key":"621_CR15","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.jval.2024.07.013","volume":"27","author":"J Lei","year":"2024","unstructured":"Lei J, Zhang J, You C, et al. First-line treatment with atezolizumab plus bevacizumab and chemotherapy for US patients with metastatic, persistent, or recurrent cervical cancer: A cost-effectiveness analysis. VALUE HEALTH. 2024;27:1528\u201334.","journal-title":"VALUE HEALTH"},{"key":"621_CR16","volume-title":"CSCO Guidelines for Ovarian Cancer Diagnosis and Treatment 2024","author":"CSOC Committee","year":"2024","unstructured":"Committee CSOC. CSCO Guidelines for ovarian cancer diagnosis and treatment 2024. Beijing: People\u2019s Medical Publishing House; 2024."},{"key":"621_CR17","volume-title":"China Integrated Oncology Guidelines (CACA) for Gynecological Tumors (Ovarian Cancer, Gestational Trophoblastic Tumor","author":"X Wu","year":"2022","unstructured":"Wu X, Fan D. China integrated oncology guidelines (CACA) for gynecological tumors (Ovarian cancer, gestational trophoblastic tumor. Tianjin: Tianjin Science and Technology Publishing House; 2022."},{"key":"621_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.annonc.2024.10.828","volume":"36","author":"P Harter","year":"2025","unstructured":"Harter P, Marth C, Mouret-Reynier MA, et al. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1\/ENGOT-ov25 trial. ANN ONCOL. 2025;36:185\u201396.","journal-title":"ANN ONCOL"},{"key":"621_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/ijgc-2023-004786","volume":"34","author":"S Cedillo","year":"2024","unstructured":"Cedillo S, Gar\u00ed C, Aceituno S, et al. Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy. INT J GYNECOL CANCER. 2024;34:277\u201384.","journal-title":"INT J GYNECOL CANCER"},{"key":"621_CR20","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.22.01010","volume":"41","author":"J Pfisterer","year":"2023","unstructured":"Pfisterer J, Joly F, Kristensen G, et al. Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer: AGO-OVAR 17 BOOST\/GINECO OV118\/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J CLIN ONCOL. 2023;41:893\u2013902.","journal-title":"J CLIN ONCOL"},{"key":"621_CR21","doi-asserted-by":"publisher","first-page":"1392903","DOI":"10.3389\/fpubh.2024.1392903","volume":"12","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Cao Q, Hong W, et al. Age and estimated glomerular filtration rate in Chinese older adults: a cohort study from 2014 to 2020. FRONT PUBLIC HEALTH. 2024;12:1392903.","journal-title":"FRONT PUBLIC HEALTH"},{"key":"621_CR22","volume-title":"Report on Nutrition and Chronic Disease Status of Chinese Residents 2020","author":"Bureau Of Disease Prevention And Control NHC","year":"2021","unstructured":"Bureau of disease prevention and control NHC. Report on nutrition and chronic disease status of Chinese residents 2020. Beijing: People\u2019s Medical Publishing House; 2021."},{"key":"621_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s41669-022-00338-2","volume":"6","author":"D Elsea","year":"2022","unstructured":"Elsea D, Fan L, Mihai A, et al. Cost-effectiveness analysis of olaparib in combination with bevacizumab compared with bevacizumab monotherapy for the first-line maintenance treatment of homologous recombination deficiency-positive advanced ovarian cancer. PHARMACOECON-OPEN. 2022;6:811\u201322.","journal-title":"PHARMACOECON-OPEN"},{"key":"621_CR24","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.3802\/jgo.2024.35.e2","volume":"35","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Yang Q, Liu K, et al. Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis. J GYNECOL ONCOL. 2024;35:e2.","journal-title":"J GYNECOL ONCOL"},{"key":"621_CR25","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1186\/1471-2407-14-984","volume":"14","author":"B Wu","year":"2014","unstructured":"Wu B, Li T, Cai J, et al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014;14:984.","journal-title":"BMC Cancer"},{"key":"621_CR26","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s12325-022-02079-4","volume":"39","author":"T Zhou","year":"2022","unstructured":"Zhou T, Cao Y, Wang X, et al. Economic evaluation of sintilimab plus bevacizumab versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma. ADV THER. 2022;39:2165\u201377.","journal-title":"ADV THER"},{"key":"621_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12904-021-00816-0","volume":"20","author":"H Wu","year":"2021","unstructured":"Wu H, Lin P, Yang S, et al. Cost-utility analysis of palliative care in patients with advanced cancer: a retrospective study. BMC PALLIAT CARE. 2021;20:126.","journal-title":"BMC PALLIAT CARE"},{"key":"621_CR28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/13696998.2022.2071066","volume":"25","author":"M Rui","year":"2022","unstructured":"Rui M, Fei Z, Wang Y, et al. Cost-effectiveness analysis of sintilimab\u2009+\u2009chemotherapy versus camrelizumab\u2009+\u2009chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China. J MED ECON. 2022;25:618\u201329.","journal-title":"J MED ECON"},{"key":"621_CR29","doi-asserted-by":"publisher","first-page":"2482019","DOI":"10.1080\/07853890.2025.2482019","volume":"57","author":"K Xu","year":"2025","unstructured":"Xu K, Yu M, Sun Q, et al. Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis. ANN MED. 2025;57:2482019.","journal-title":"ANN MED"},{"key":"621_CR30","doi-asserted-by":"publisher","first-page":"e312133","DOI":"10.1371\/journal.pone.0312133","volume":"19","author":"J Peng","year":"2024","unstructured":"Peng J, Xu H, Liu Q. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis. PLoS ONE. 2024;19:e312133.","journal-title":"PLoS ONE"},{"key":"621_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ygyno.2023.05.010","volume":"174","author":"Y Qiu","year":"2023","unstructured":"Qiu Y, Zha J, Ma A, et al. Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer. GYNECOL ONCOL. 2023;174:175\u201381.","journal-title":"GYNECOL ONCOL"},{"key":"621_CR32","doi-asserted-by":"publisher","first-page":"1477146","DOI":"10.3389\/fimmu.2024.1477146","volume":"15","author":"M You","year":"2024","unstructured":"You M, Luo L, Lu T, et al. Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer. FRONT IMMUNOL. 2024;15:1477146.","journal-title":"FRONT IMMUNOL"},{"key":"621_CR33","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1111\/ajco.12581","volume":"13","author":"B Nafees","year":"2017","unstructured":"Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: An international study. ASIA-PAC J CLIN ONCO. 2017;13:e195\u2013203.","journal-title":"ASIA-PAC J CLIN ONCO"},{"key":"621_CR34","doi-asserted-by":"publisher","first-page":"14871","DOI":"10.1002\/cam4.5724","volume":"12","author":"Z Xu","year":"2023","unstructured":"Xu Z, Ye ZM, Tang YK, et al. Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China. CANCER MED-US. 2023;12:14871\u201380.","journal-title":"CANCER MED-US"},{"key":"621_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","volume":"24","author":"X Yue","year":"2021","unstructured":"Yue X, Li Y, Wu J, et al. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. VALUE HEALTH REG ISS. 2021;24:1\u201305.","journal-title":"VALUE HEALTH REG ISS"},{"key":"621_CR36","first-page":"501","volume":"42","author":"B Chen","year":"2021","unstructured":"Chen B, Fan C. Pharmacoeconomic evaluation of olaparib monotherapy in patients with newly diagnosed advanced BRCA mutation epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. WORLD Clin DRUGS. 2021;42:501\u201308.","journal-title":"WORLD Clin DRUGS"},{"key":"621_CR37","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40261-025-01439-6","volume":"45","author":"M Han","year":"2025","unstructured":"Han M, Jung HI, Chen YF, et al. Economic evaluation of penpulimab plus paclitaxel and carboplatin combination therapy as first-line treatment for locally advanced or metastatic squamous non-small cell lung cancer in China. CLIN DRUG INVEST. 2025;45:283\u201394.","journal-title":"CLIN DRUG INVEST"},{"key":"621_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13048-023-01257-4","volume":"16","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Cao H, et al. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial. J OVARIAN RES. 2023;16:168.","journal-title":"J OVARIAN RES"},{"key":"621_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pharp.2025.03.004","volume":"1","author":"S Hu","year":"2025","unstructured":"Hu S, Yang S, Cai W. Keeping up with international frontier and promoting research and development of pharmacoeconomics in China. Pharmacoeconomics Policy. 2025;1:2\u201304.","journal-title":"Pharmacoeconomics Policy"},{"key":"621_CR40","first-page":"50","volume":"42","author":"M Yang","year":"2023","unstructured":"Yang M, Dai Z, Lu Y, et al. Fitting and extrapolation methods of survival curve in pharmacoeconomic evaluation and the comparative study. Chin Health Econ. 2023;42:50\u20138.","journal-title":"Chin Health Econ"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00621-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00621-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00621-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:03:23Z","timestamp":1784693003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00621-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00621-1","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is based on non-individual patient data, and did not include the use of human participants or animals. Therefore, ethical review and approval were not required for the study.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"48"}}